51 completed, 36 recruiting, 23 terminated, 20 active not recruiting. 50 Phase 2, 48 Phase 1, 34 Not applicable, 7 Phase 3, 3 Early Phase 1.
Follow Ovarian Carcinoma: new trials by email Literature Review of Ovarian Carcinoma trials Research Report on Ovarian Carcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| IGFBP-2 Vaccine to Prevent Ovarian Cancer Progression in Patients With Serologic Detection of Recurrence pUMVC3-hIGFBP-2 Multi-epitope Plasmid DNA Vaccine, Carboplatin, Computed Tomography - Fallopian Tube Carcinoma, Ovarian Carcinoma | Phase 2 | Recruiting | University of Washington | 26 | 2026-09-16 | 2026-11-02 |
| A Blended e-Health Intervention to Improve Fear of Progression in Women With Gynecologic or Breast Cancer Best Practice, Interview, Supportive Care - Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8 | Not applicable | Recruiting | City of Hope Medical Center | 126 | 2026-09-09 | 2026-10-16 |
| Adapted Helping Ovarian Cancer Patients Cope Intervention to Address Burnout for Gynecologic Oncology Clinicians Behavioral Intervention, Interview, Survey Administration - Ovarian Carcinoma, Psychiatric Disorder | Not applicable | Recruiting | Fred Hutchinson Cancer Center | 25 | 2026-02-24 | 2026-06-17 |
| Ultrasound Microvessel Imaging for the Evaluation of Ovarian and Adnexal Lesions Transvaginal Ultrasound, Ultrasound Microvessel Imaging - Female Reproductive System Adnexal Neoplasm, Ovarian Carcinoma | Not applicable | Recruiting | Mayo Clinic | 40 | 2026-01-22 | 2026-02-03 |
| The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding Areas Cancer Therapeutic Procedure, Questionnaire Administration - Amyloidosis, Basal Cell Carcinoma | Phase 2 | Recruiting | Mayo Clinic | 27 | 2025-12-18 | 2026-09-30 |
| Contribution of Oncovascular Surgery in the Treatment of Gynecological Advanced Malignant Diseases. Ovarian Carcinoma, Cervical Carcinoma | Not yet recruiting | National Cancer Institute, Naples | 130 | 2025-12-01 | 2025-12-05 | |
| DT2216 + Paclitaxel in Platinum-Resistant Ovarian Cancer DT2216, Paclitaxel - Ovarian Cancer, Ovarian Carcinoma | Phase 1 | Recruiting | Elizabeth Stover, MD, PhD | 30 | 2025-09-22 | 2026-09-11 |
| Determining the Biodistribution of an Imaging Tracer (68Ga-FAPi-46) in Patients With Solid Tumors or Hematologic Cancers Computed Tomography, Fludeoxyglucose F-18, Gallium Ga 68 FAPi-46 - Anal Carcinoma, Bladder Carcinoma | Phase 1 | Active not recruiting | Jonsson Comprehensive Cancer Center | 30 | 2025-08-01 | 2026-10-20 |
| A Long-Term Follow-Up Study of Participants Treated With A2 Biotherapeutics (A2 Bio) Gene Therapy (GT) Products No additional intervention administered in this long term follow-up study - Solid Tumor Cancer, Solid Tumor, Unspecified, Adult | Enrolling by invitation | A2 Biotherapeutics Inc. | 400 | 2025-07-31 | 2026-05-20 | |
| A Phase 1 Study of ATV-1601 in Patients With Advanced Cancer That Have AKT1 E17K Mutations ATV-1601, ATV-1601 + Fulvestrant - Advanced Solid Tumors, Breast Cancer | Phase 1 | Active not recruiting | Atavistik Bio, Inc | 134 | 2025-07-29 | 2026-08-07 |
| The Vanguard Study: Testing a New Way to Screen for Cancer Biospecimen Collection, Device Usage, Electronic Health Record Review - Bladder Carcinoma, Breast Carcinoma | Not applicable | Recruiting | National Cancer Institute (NCI) | 24000 | 2025-06-18 | 2026-11-06 |
| Benefit of Transcutaneous Auricular Vagus Nerve Stimulation in Improving Quality of Life in First Line Treatment of Ovarian Cancer: transcutaneous auricular vagus nerve stimulation, Placebo device - Ovarian Carcinoma, First Line Chemotherapy | Phase 3 | Recruiting | Centre Francois Baclesse | 116 | 2025-04-30 | 2025-10-07 |
| Sequential CD146 and GPC3 CAR-T Cell Therapy in Advanced Ovarian Cancer GPC3 CD146 CAR-T cells - Ovarian Cancer, Ovarian Carcinoma | Phase 1 / Phase 2 | Recruiting | Essen Biotech | 80 | 2025-04-29 | 2025-07-16 |
| Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer Bevacizumab, Biospecimen Collection, Computed Tomography - Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube High Grade Serous Adenocarcinoma | Phase 3 | Recruiting | NRG Oncology | 880 | 2025-03-12 | 2026-08-07 |
| Feasibility of Saliva and Remote Monitoring of Active Cytomegalovirus (CMV) Infection and Symptoms During Ovarian Cancer Treatment Non-Interventional Study - Cancer-related Cognitive Dysfunction, Cytomegaloviral Infection | Completed | Mayo Clinic | 49 | 2025-03-07 | 2025-12-04 | |
| Pilot Randomized Controlled Trial of a Collaborative Agenda-setting Intervention (CASI) for Patients With Ovarian Cancer Collaborative Agenda-Setting Intervention - Ovarian Cancer, Ovarian Neoplasms | Not applicable | Recruiting | Dana-Farber Cancer Institute | 112 | 2025-01-17 | 2026-06-17 |
| OveRcoming immunosupprEssion aNd rebAlancing the Immune reSponSe in ovAriaN CancEr Study Bone marrow aspiration, Vena puncture, Peritoneal fluid - Ovarian Neoplasms, Ovarian Cancer | Not applicable | Recruiting | Gynaecologisch Oncologisch Centrum Zuid | 90 | 2025-01-01 | 2025-12-12 |
| Belzutifan in Recurrent Clear Cell Carcinoma of Gynecologic Origin Belzutifan - Ovarian Cancer, Ovarian Carcinoma | Phase 2 | Recruiting | Dana-Farber Cancer Institute | 32 | 2024-12-20 | 2025-11-05 |
| Intraperitoneal Cytokine-Induced Memory Like (CIML) Natural Killer (NK) Cells in Recurrent Ovarian Cancer Cytokine-Induced Memory-like Natural Killer Cells, Interleukin 2 - Platinum-resistant Ovarian Cancer, Recurrent Ovary Cancer | Phase 1 | Recruiting | Dana-Farber Cancer Institute | 18 | 2024-10-09 | 2026-06-16 |
| A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors NKT3964, Paclitaxel, Doxorubicin - Solid Tumor, Advanced Solid Tumor | Phase 1 | Recruiting | NiKang Therapeutics, Inc. | 238 | 2024-09-19 | 2026-11-05 |
Showing 20 of 155. Sign in to see all of them.
Ovarian Neoplasms (155) · Fallopian Tube Neoplasms (38) · Endometrial Neoplasms (29) · Breast Neoplasms (28) · Uterine Cervical Neoplasms (19) · Colorectal Neoplasms (18) · Triple Negative Breast Neoplasms (17) · Carcinoma, Non-Small-Cell Lung (16) · Melanoma (15) · Pancreatic Neoplasms (14) · Prostatic Neoplasms (14) · Carcinoma, Renal Cell (13) · Stomach Neoplasms (12) · Lung Neoplasms (11) · Neoplasm Metastasis (10)
Adnexal Diseases (155) · Endocrine Gland Neoplasms (155) · Endocrine System Diseases (155) · Female Urogenital Diseases (155) · Female Urogenital Diseases and Pregnancy Complications (155) · Genital Diseases (155) · Genital Diseases, Female (155) · Gonadal Disorders (155) · Urogenital Diseases (155) · Neoplasms by Site (154) · Urogenital Neoplasms (154) · Ovarian Diseases (153) · Genital Neoplasms, Female (151) · Neoplasms (145) · Neoplasms by Histologic Type (46)
Paclitaxel (15) · Carboplatin (12) · Magnetic Resonance Spectroscopy (11) · Bevacizumab (9) · Specimen Handling (8) · Docetaxel (5) · Taxes (5) · olaparib (5) · Cyclophosphamide (4) · Hyperthermic Intraperitoneal Chemotherapy (4) · Interviews as Topic (4) · Palliative Care (4) · Practice Guidelines as Topic (4) · Standard of Care (4) · liposomal doxorubicin (4)
National Cancer Institute (NCI) (10) · M.D. Anderson Cancer Center (9) · City of Hope Medical Center (4) · Dana-Farber Cancer Institute (4) · Gynecologic Oncology Group (4) · Mayo Clinic (4) · NRG Oncology (4) · Pfizer (4) · Memorial Sloan Kettering Cancer Center (3) · A2 Biotherapeutics Inc. (2) · Fred Hutchinson Cancer Center (2) · Institut Bergonié (2) · Jonsson Comprehensive Cancer Center (2) · Jules Bordet Institute (2) · Lei Li (2)
United States (101) · France (14) · China (10) · Belgium (9) · Italy (7) · Spain (7) · Canada (6) · South Korea (6) · Netherlands (5) · Germany (4) · Israel (4) · Japan (4) · Puerto Rico (4) · Taiwan (4) · United Kingdom (3)
Lei Li, M.D. (2) · Sanjiv Gambhir (2) · Aaron H Wolfson, MD (1) · Agustin Garcia, MD (1) · Akira Hirasawa, M.D., Ph.D. (1) · Alessandro Santin, M.D. (1) · Allison Quick, MD (1) · Amanika Kumar, MD (1) · Amina Ahmed (1) · Anne Reb (1) · Anthony Elias, MD (1) · Apostolos Sarivalasis, MD (1) · Armando Sardi, M.D. (1) · Arturo Molina, MD (1)
PMID 36459691, PMID 36512649, PMID 21862407, PMID 22847809, PMID 23922302, PMID 23988418, PMID 26111920, PMID 26586415, PMID 26961146, PMID 28275119, PMID 29995186, PMID 30347019, PMID 30862609, PMID 31708167, PMID 31822399, PMID 31912673, PMID 32463741, PMID 33048619, PMID 33277073, PMID 33358206, PMID 33610319, PMID 33909232, PMID 34548240, PMID 34562230, PMID 34882500, PMID 34965890, PMID 35133871, PMID 35138919, PMID 35537408, PMID 36214786, PMID 36351402, PMID 36675280, PMID 36946440, PMID 37053535, PMID 37129197, PMID 37185961, PMID 37322121, PMID 37735588, PMID 37934000, PMID 38514101, PMID 38591867, PMID 38719544, PMID 38741776, PMID 39108617, PMID 39208372, PMID 39509704, PMID 39666929, PMID 39693587, PMID 39816915, PMID 39913886
U10CA101165 (4), P30CA016672 (3), U10CA180868 (3), UG1CA189867 (3), UM1CA186690 (3), UM1CA186716 (3), UM1CA186717 (3), 2023 (2), P30CA015704 (2), P30CA033572 (2), P30CA047904 (2), U01CA062505 (2), U01CA099168 (2), U10CA027469 (2), UM1CA186691 (2)